RU2010152562A - Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта - Google Patents
Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта Download PDFInfo
- Publication number
- RU2010152562A RU2010152562A RU2010152562/10A RU2010152562A RU2010152562A RU 2010152562 A RU2010152562 A RU 2010152562A RU 2010152562/10 A RU2010152562/10 A RU 2010152562/10A RU 2010152562 A RU2010152562 A RU 2010152562A RU 2010152562 A RU2010152562 A RU 2010152562A
- Authority
- RU
- Russia
- Prior art keywords
- replicase
- alphavirus
- expression vector
- sequence
- seq
- Prior art date
Links
- 108010026228 mRNA guanylyltransferase Proteins 0.000 title claims abstract 38
- 239000013604 expression vector Substances 0.000 title claims abstract 18
- 239000000568 immunological adjuvant Substances 0.000 title 1
- 241000710929 Alphavirus Species 0.000 claims abstract 22
- 229960005486 vaccine Drugs 0.000 claims abstract 8
- 239000013598 vector Substances 0.000 claims abstract 7
- 101800000980 Protease nsP2 Proteins 0.000 claims abstract 5
- 238000011282 treatment Methods 0.000 claims abstract 5
- 239000002671 adjuvant Substances 0.000 claims abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 210000000987 immune system Anatomy 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 208000035473 Communicable disease Diseases 0.000 claims abstract 2
- 108060004795 Methyltransferase Proteins 0.000 claims abstract 2
- 241000710961 Semliki Forest virus Species 0.000 claims abstract 2
- 239000000470 constituent Substances 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000007999 Nuclear Proteins Human genes 0.000 claims 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7189808P | 2008-05-23 | 2008-05-23 | |
| US61/071,898 | 2008-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010152562A true RU2010152562A (ru) | 2012-06-27 |
Family
ID=40910781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010152562/10A RU2010152562A (ru) | 2008-05-23 | 2009-05-22 | Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9474800B2 (enExample) |
| EP (1) | EP2296702A1 (enExample) |
| JP (1) | JP5663474B2 (enExample) |
| KR (1) | KR20110044836A (enExample) |
| CN (1) | CN102083463B (enExample) |
| AU (1) | AU2009248735B2 (enExample) |
| BR (1) | BRPI0913045A2 (enExample) |
| CA (1) | CA2724570A1 (enExample) |
| IL (1) | IL209077A0 (enExample) |
| MX (1) | MX2010012587A (enExample) |
| NZ (1) | NZ589495A (enExample) |
| RU (1) | RU2010152562A (enExample) |
| SG (1) | SG191600A1 (enExample) |
| WO (1) | WO2009141434A1 (enExample) |
| ZA (1) | ZA201007880B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220119D0 (en) * | 2012-11-08 | 2012-12-26 | Univ Cork | Vector |
| CN111304201B (zh) * | 2020-02-21 | 2022-10-21 | 华南农业大学 | 一种降低乙型脑炎脑病毒感染的siRNA及其应用 |
| JP2023517644A (ja) * | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| CN113846113B (zh) * | 2021-09-09 | 2022-09-13 | 臻赫医药(杭州)有限公司 | 一种有限自我复制mRNA分子系统、制备方法及应用 |
| JP2025504364A (ja) * | 2022-01-08 | 2025-02-12 | カロジェン コーポレイション | 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン |
| KR20240049429A (ko) | 2022-10-08 | 2024-04-16 | 최주언 | 황금비율 계량컵 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5684136A (en) * | 1992-05-18 | 1997-11-04 | Genentech, Inc. | Chimeric hepatocyte growth factor (HGF) ligand variants |
| SE9401091D0 (sv) * | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) * | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| JP2002521461A (ja) * | 1998-07-29 | 2002-07-16 | インビトロゲン・コーポレーション | Ｒｎａウイルスを用いる組換えタンパク質の調節発現 |
| EP1226238A2 (en) * | 1999-10-27 | 2002-07-31 | Cytos Biotechnology AG | Method for creating divergent populations of nucleic acid molecules and proteins |
| WO2002057316A1 (en) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Novel monoclonal antibody |
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| US20060251620A1 (en) * | 2002-08-22 | 2006-11-09 | Lidia Ivanova | Inducible alphaviral/orip based gene expression system |
| ES2222095B1 (es) * | 2003-07-02 | 2005-11-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia | Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones. |
| AU2005327198B2 (en) * | 2004-07-09 | 2011-03-31 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| AU2007342333B2 (en) * | 2006-09-12 | 2013-02-28 | Alphavax, Inc. | Alphavirus replicon particles encoding IL- 12 as immunological adjuvants |
| WO2008065225A2 (es) * | 2006-11-28 | 2008-06-05 | Proyecto De Biomedicina Cima, S.L. | Vector viral y sus aplicaciones |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
-
2009
- 2009-05-22 CA CA2724570A patent/CA2724570A1/en not_active Abandoned
- 2009-05-22 WO PCT/EP2009/056240 patent/WO2009141434A1/en not_active Ceased
- 2009-05-22 BR BRPI0913045A patent/BRPI0913045A2/pt not_active IP Right Cessation
- 2009-05-22 MX MX2010012587A patent/MX2010012587A/es not_active Application Discontinuation
- 2009-05-22 CN CN200980118773.7A patent/CN102083463B/zh not_active Expired - Fee Related
- 2009-05-22 KR KR1020107029034A patent/KR20110044836A/ko not_active Ceased
- 2009-05-22 AU AU2009248735A patent/AU2009248735B2/en not_active Ceased
- 2009-05-22 SG SG2013039953A patent/SG191600A1/en unknown
- 2009-05-22 NZ NZ589495A patent/NZ589495A/en not_active IP Right Cessation
- 2009-05-22 EP EP09749924A patent/EP2296702A1/en not_active Withdrawn
- 2009-05-22 RU RU2010152562/10A patent/RU2010152562A/ru not_active Application Discontinuation
- 2009-05-22 US US12/993,987 patent/US9474800B2/en not_active Expired - Fee Related
- 2009-05-22 JP JP2011509995A patent/JP5663474B2/ja not_active Expired - Fee Related
-
2010
- 2010-11-02 IL IL209077A patent/IL209077A0/en unknown
- 2010-11-03 ZA ZA2010/07880A patent/ZA201007880B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011523642A (ja) | 2011-08-18 |
| US9474800B2 (en) | 2016-10-25 |
| JP5663474B2 (ja) | 2015-02-04 |
| AU2009248735B2 (en) | 2015-08-20 |
| MX2010012587A (es) | 2011-05-25 |
| CN102083463A (zh) | 2011-06-01 |
| SG191600A1 (en) | 2013-07-31 |
| EP2296702A1 (en) | 2011-03-23 |
| BRPI0913045A2 (pt) | 2017-05-23 |
| CA2724570A1 (en) | 2009-11-26 |
| NZ589495A (en) | 2012-06-29 |
| US20110171255A1 (en) | 2011-07-14 |
| AU2009248735A1 (en) | 2009-11-26 |
| ZA201007880B (en) | 2012-02-29 |
| WO2009141434A1 (en) | 2009-11-26 |
| KR20110044836A (ko) | 2011-05-02 |
| IL209077A0 (en) | 2011-01-31 |
| WO2009141434A4 (en) | 2010-01-14 |
| CN102083463B (zh) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pugachev et al. | Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection | |
| JP7189014B2 (ja) | Ｒｓｖに対するワクチン | |
| CN116472279A (zh) | 麻疹载体covid-19免疫原性组合物和疫苗 | |
| CN113151184B (zh) | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 | |
| RU2011128371A (ru) | Модифицированные f протеины sv и способы их применения | |
| BRPI0417509A (pt) | molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira | |
| UA68327C2 (en) | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals | |
| CN105769931A (zh) | 溶瘤弹状病毒 | |
| RU2015135890A (ru) | Композиция вакцины | |
| US20210346492A1 (en) | SARS-CoV-2 Vaccines | |
| KR20050010000A (ko) | Ｈｉｖ 조절/부속 단백질의 융합 단백질 | |
| MY197684A (en) | Oncolytic virus and method | |
| EA003554B1 (ru) | Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного | |
| JP2011523642A5 (enExample) | ||
| WO2009141434A4 (en) | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | |
| JP2026063215A5 (enExample) | ||
| CN102112601A (zh) | 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途 | |
| JP7841847B2 (ja) | ラッサワクチン | |
| WO2021254270A1 (zh) | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 | |
| MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
| WO2019163781A1 (ja) | エンテロウイルスワクチン | |
| US20250026793A1 (en) | Chimeric betacoronavirus spike polypeptides | |
| CN113248608B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其用途 | |
| US20230302083A1 (en) | Highly-networked coronavirus immunogen composition | |
| CN102464721B (zh) | 针对人肠道病毒71型的重组广谱性疫苗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140801 |